Patricia S Andrews has bought stock on 2 days since Nov 2021

Patricia S. Andrews is an accomplished biopharmaceutical executive and public company board member with extensive experience in corporate strategy, product commercialization, and business development.( She was appointed to the Board of Directors of Oncolytics Biotech Inc. (ONCY) as a Director in January 2024, bringing her expertise in oncology trials and partnerships to support the company's advancement of pelareorep toward registrational studies in breast and pancreatic cancers.(

Andrews previously served as Chief Executive Officer of Sumitomo Pharma Oncology, Inc., leading integration efforts, completing three Phase 3 trials, and expanding the pipeline from two to eight programs.( Before that, as Chief Commercial Officer at Incyte, she oversaw the launch of Jakafi® for myelofibrosis and key licensing deals with Novartis and Eli Lilly.( Earlier, she spent 17 years at Pfizer, rising to Vice President and General Manager of the U.S. Oncology Business Unit, where she launched Sutent® as the market leader in renal cell carcinoma and revitalized Camptosar® sales.( She currently serves as a Director and Audit Committee member at GlycoMimetics, aiding its first Phase 3 study and commercialization preparations.( Andrews holds an MBA from the University of Michigan and a BA from Brown University.(

Written by Perplexity from public sources.